Hosted on MSN1mon
J&J Trading Near 52-Week Low: Should You Sell the Stock?J&J’s Innovative Medicine unit is performing at above-market levels. Its growth is driven by existing products like Darzalex, Stelara, Tremfya, Uptraviand Erleada and the continued uptake of new ...
Zacks.com on MSN5d
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them," noted Bill Martin, J&J Innovative Medicine's ...
global therapeutic area head of Neuroscience at Johnson & Johnson Innovative Medicine, said in a statement. Patients could experience improvements in their symptoms as early as 24 hours without ...
J&J’s Innovative Medicine unit is showing a growing trend. The segment’s sales rose 5.8% in 2024 on an organic basis. In 2025, J&J expects growth in the Innovative Medicine segment despite the ...
Kevin Hamill, President, U.S. Immunology, Johnson & Johnson Innovative Medicine ... “As a company, J&J is committed to leading where medicine is going,” Hamill says.
However, this figure represents an almost 11% decline from the previous year. Furthermore, J&J's innovative medicine unit generated $14.33 billion in sales, while its medtech unit reached $8.19 ...
Picture: Darragh Kane Pharmaceutical giant Johnson & Johnson Innovative Medicine (J&J IM) was named Company of the Year at Cork Chamber’s annual dinner in Cork City Hall on Friday. The company ...
It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism ...
Sales in J&J’s Innovative Medicines segment rose 4.4% ... Sales of blockbuster multiple myeloma medicine Darzalex rose 20.9% year over year to $3.08 billion in the quarter.
The PhRMA Foundation announced the appointment to its Board of Directors of Dr. John C. Reed, MD, PhD, Executive Vice President of Innovative Medicine R&D at Johnson & Johnson (J&J), and Dr. Donatello ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback